Introduction
============

Breast cancer is the most common malignancy among women in the world and accounts for 22.9% of all worldwide cancer cases and \>450,000 cancer-related deaths annually. Due to the recent advancement in early detection, prevention, and treatment options, survival of breast cancer patients has significantly improved, especially for estrogen receptor (ER)- and progesterone receptor (PR)-positive breast cancer. However, there is less improvement for triple-negative breast cancer (TNBC). TNBC, a lack of ER, PR, and HER2 expression, accounts for 15%--20% of all breast cancer cases.[@b1-ott-7-1733]--[@b3-ott-7-1733] TNBC is characterized by poor survival and a high probability of early treatment relapse, especially distant metastasis.[@b4-ott-7-1733]--[@b6-ott-7-1733] Due to the lack of hormone receptor and HER2 expression, treatment options for patients with TNBC are limited to cytotoxic chemotherapy. Thus, there is an urgent need for elucidation of novel targets for TNBC therapy and to improve the poor prognosis for the patients. The proclivity of breast cancer metastasis to particular organs may be mediated by specific genes.[@b7-ott-7-1733]--[@b9-ott-7-1733]

ETS translocation variant 4 (ETV4) is a member of the PEA3 subfamily of ETS (E-26) transcription factor.[@b10-ott-7-1733] Due to sharing conserved ETS deoxyribonucleic acid (DNA) binding domains, ETV4 binds to targeting gene promoter dictated by specific sequence elements bearing a conserved 5′-GGAA/T-3′ motif.[@b11-ott-7-1733] ETV4 protein is generally expressed at low levels in normal adult tissue, but the expression levels of messenger ribonucleic acid (mRNA) and protein are much higher in several cancer tissue types, including breast, colorectal, and esophageal cancers and ovarian tumor, implicating the possibility of ETV4 as an oncogenic protein to promote cancer development and progression.[@b12-ott-7-1733]--[@b16-ott-7-1733] The most frequently studied role of ETV4 in cancer development and progression is its ability to promote cancer metastasis.[@b13-ott-7-1733],[@b14-ott-7-1733],[@b17-ott-7-1733] For example, a previous study showed that the nuclear translocation of ETV4 was induced by epidermal growth factor receptor and that the elevated ETV4 expression might promote ovarian tumor cell invasion by activating matrix metalloproteinase (MMP)-9 and MMP-14 expression.[@b14-ott-7-1733] In breast cancer, ETV4 was reported to be overexpressed in estradiol receptor-negative breast cancer cell lines and in estradiol receptor-negative tissue.[@b18-ott-7-1733]--[@b21-ott-7-1733] These data together indicate that ETV4 protein may play a role in regulation of tumor progression and distant metastasis.

Thus, in the current study, we first performed a tumor metastasis-related gene expression array analysis in TNBC tissue specimens and found that expression of ETV4 protein was induced; thus, we then detected expression of ETV4 protein in a larger sample size of TNBC tissue specimens for the association of ETV4 expression with clinicopathological features and disease relapse and prognosis of the patients. Our data demonstrated that overexpression of ETV4 protein was associated with increasing risk of TNBC distant metastasis and poor survival of the patients.

Materials and methods
=====================

Breast cancer tissue samples
----------------------------

In this present study, we obtained five cases of fresh TNBC tissue and five cases of luminal subtype fresh breast tumor tissue from the Department of Breast Surgery, Sun Yat-Sen University Cancer Center, Guangzhou, People's Republic of China. TNBC refers to ER negative, PR negative, and HER2 negative; luminal subtype refers to ER and/or PR positive but HER2 negative. With respect to ER or PR expression determined by immunohistochemistry (IHC), detection of \<1% neoplastic cells was considered negative. HER2 was determined initially by IHC and graded from 0 to 3+. HER2 negative was defined as HER2 graded 0 or 1+, and positive was defined as 3+. Scores of HER2 2+ were confirmed as either HER2 negative or HER2 positive according to fluorescence in situ hybridization analysis.

In addition, to detect ETV4 expression, we also obtained 135 female patients with TNBC diagnosed without any evidence of distant metastasis at the time of surgery between January 2000 and December 2008 at Sun Yat-Sen University Cancer Center. The cases selected were based on distinctive pathologic diagnosis of invasive breast cancer, availability of complete medical records and follow-up data, but lack of ER, PR, and HER2 expression. All patients were staged according to the American Joint Committee on Cancer Tumor Node Metastasis Staging System for Breast Cancer (AJCC 2010, seventh edition). The formalin-fixed and paraffin-embedded tissue specimens were retrieved from the archives of the Department of Pathology of Sun Yat-Sen University Cancer Center. Tissue microarrays (TMAs) were then constructed as described previously.[@b22-ott-7-1733] Each sample was arrayed in triplicate to minimize tissue loss and to overcome tumor heterogeneity. In addition, normal breast tissue was obtained from three patients undergoing breast biopsies, who were subsequently not diagnosed with breast cancer.

All sample donors gave written informed consent. The use of these samples involved in our study was approved by the Institute Research Medical Ethics Committee of Sun Yat-Sen University.

Tumor metastasis-related gene expression profiling
--------------------------------------------------

Differential expression of tumor metastasis-related genes was analyzed in a Human Tumor Metastasis PCR (polymerase chain reaction) Array (APHS-028A; SuperArray Inc.) obtained from Kangchen Genechip (Shanghai, People's Republic of China) according to the manufacturer's instructions. Briefly, RNA was extracted from TNBC tissue using Trizol (Invitrogen, Carlsbad, CA, USA) and cleared up using an RNeasy^®^ MinElute™ Cleanup Kit (Qiagen, Valencia, CA, USA). Subsequently, total RNA samples were reversely transcribed into complementary DNA (cDNA) using SuperScript III Reverse Transcriptase (Invitrogen), and these cDNA samples were amplified by PCR in 2× Super Array PCR Master Mix (SuperArray Bioscience, Frederick, MD, USA). Real-time PCR was then performed on each sample using the Human Tumor Metastasis RT^2^ Profiler™ PCR Array (SuperArray Bioscience) in an Opticon™ DNA Engine ABI Prism system (Applied Biosystems, Foster City, CA, USA), according to the manufacturer's instructions. Data were normalized for glyceraldehyde 3-phosphate dehydrogenase (GAPDH) levels by the ΔΔCt method.

Cell lines and culture
----------------------

Breast cancer T47D, MDA-MB-453, MDA-MB-415, MCF-7, MDA-MB-231, MDA-MB-435, ZR-75-30, and BT474 cell lines were obtained from ATCC and cultured with Dulbecco's Modified Eagle's Medium (Gibco BRL, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (HyClone) in a humidified incubator with 5% CO~2~ and 95% air.

Protein extraction and Western blot
-----------------------------------

Cultured cells at 70%--80% confluence were harvested, washed three times in phosphate-buffered saline, and lysed in a sodium dodecyl sulfate lysis buffer. Western blot analysis was performed using an anti-ETV4 antibody (Sigma-Aldrich, St Louis, MO, USA). The blotted membranes were then stripped and reprobed with anti-GAPDH as a loading control.

RNA extraction and real-time reverse transcription PCR
------------------------------------------------------

Total RNA was extracted from cultured cells using a Trizol reagent (Invitrogen) according to the manufacturer's instructions, and then 1.5 μg of total RNA samples of each cell line was used for cDNA synthesis with random hexamers. The cDNA samples were subsequently amplified and quantified using the ABI Prism 7500 Sequence Detection System (Applied Biosystems) with SYBR Green I dye (Molecular Probes, Invitrogen) with ETV4 primers (5′-CCCATCTCAGTCACT GGCATT-3′ and 5′-CCGCCAACATCTCCTTGbTTC-3′) and GAPDH (5′-ACCACAGTCCATGCCATCAC-3′ and 5′-TCCACCACCCTGTTGCTGTA-3′). The expression of ETV4 was normalized to the internal reference GAPDH levels using the formula 2-\[(Ct of ETV4)--(Ct of GAPDH)\], where Ct represents the threshold cycle for each transcript.

IHC
---

TMA blocks containing 135 cases of TNBC tissue samples were cut into 5 μm sections and processed for IHC as described previously.[@b22-ott-7-1733] After the TMA sections were incubated with a primary antibody against ETV4 (1:500; Santa Cruz Biotechnology, Santa Cruz, CA, USA) overnight at 4°C, the stained TMA sections were reviewed and quantitatively analyzed using the AxioVision Rel. 4.6 computerized image analysis system assisted by an automatic measurement program (Carl Zeiss, Oberkochen, Germany). Meanwhile, according to the manufacturer's recommendations, lymphocytes and K-562 cells were used as negative controls and positive controls, respectively. The staining intensity score (representing the average staining intensity of ETV4-positive cells) was assigned as 1, no staining; 2, weak staining; 3, moderate staining; and 4, strong staining. Percentage of tumor cells stained was scored as 1, \<10%; 2, 10%--30%; 3, 30%--75%; and 4, \>75%. After that, these two scores were multiplied to calculate the staining index and obtain values of 1, 2, 3, 4, 6, 8, 9, 12, or 16. A median staining index for all of the TNBC samples was used as a cutoff value to define high and low expression of ETV4, and then a score of ≥8 was defined as high ETV4 expression and scores of ≤6 defined as low ETV4 expression. All cases were scored by two independent observers.

Statistical analysis
--------------------

Clinicopathological parameters were assessed between two subgroups by the chi-square test. Cumulative survival probabilities were calculated through the Kaplan--Meier method. Survival rates were compared by log-rank test. Multivariate analyses were performed by the Cox regression model. Subsequently, variables with traditional prognostic factors such as age at diagnosis, tumor size, lymph node involvement, pathologic stage, and lymphovascular invasion were included to the multivariate analysis with enter model. All statistical tests were two-tailed, and *P*,0.05 was considered significant. All statistical analyses were performed using SPSS 17.0 (SPSS Inc., Chicago, IL, USA).

In addition, disease-free survival (DFS) was defined as the interval from the date of operation to the date of first recurrence. Overall survival (OS) was calculated as a period from the date of diagnosis to the date of death. Locoregional relapse-free survival was defined as the interval from the first treatment for breast cancer to the first locoregional relapse. Distant metastasis-free survival was calculated as a period from the date of diagnosis to the date of distant metastasis or contralateral breast cancer. Locoregional relapse was defined as the recurrence either in the treated breast or in the ipsilateral lymph node-bearing area (axillary, internal mammary, supraclavicular node).

Results
=======

Upregulation of ETV4 expression in TNBC tissue specimens
--------------------------------------------------------

In this study, we first profiled differential expression of tumor metastasis-related genes in five cases of TNBC tissue samples compared with that of five luminal subtype (ER and/or PR positive and HER2 negative) breast tumor tissue using a Human Tumor Metastasis RT^2^ Profiler™ PCR Array containing 84-cell metastasis-related genes. Our data showed that there are a total of eight upregulated (CCL7, KISS1, MET, MMP7, NR4A3, ETV4, TIMP3, and TSHR) and three downregulated (ITGA7, SSTR, and MMP2) genes (more than three-fold) identified in between TNBC tissue and luminal subtype breast cancer tissue. The levels of ETV4 mRNA in TNBC tissue were more than five-fold upregulated compared with those of luminal subtype breast tumor tissue ([Table 1](#t1-ott-7-1733){ref-type="table"} and [Figure 1](#f1-ott-7-1733){ref-type="fig"}), suggesting that the ETV4 gene might be involved in TNBC distant metastasis.

Increased ETV4 expression in TNBC cell lines and tissue specimens
-----------------------------------------------------------------

To verify the array data, we performed Western blotting and real-time PCR analyses of ETV4 expression in TNBC cell lines and tissue specimens. We found that the expression of both ETV4 mRNA and protein was notably upregulated in hormone receptor-negative or TNBC cell lines tested (MDA-MB453, MDA-MB-231, and MDA-MB-435) compared with hormone receptor-positive cells (T47D, MDA-MB-415, MCF-7, ZR-75-30, BT474; [Figure 2A and B](#f2-ott-7-1733){ref-type="fig"}). Furthermore, the data on eight pairs of TNBC tissue and adjacent normal breast tissue samples showed that expression of ETV4 mRNA and protein was also significantly higher in TNBC tissue than in the adjacent normal breast tissue ([Figure 2C--E](#f2-ott-7-1733){ref-type="fig"}), indicating that ETV4 is overexpressed in TNBC cells and tissue. Also, results of IHC on eight pairs of tissue samples as described showed that ETV4 protein was positively expressed in TNBC tissue but not in the adjacent normal breast tissue.

IHC analysis of ETV4 expression in TNBC tissue specimens
--------------------------------------------------------

To further explore whether ETV4 overexpression in TNBC was associated with the clinical outcomes, we analyzed ETV4 expression via IHC in 135 paraffin-embedded archived TNBC tissue samples. As shown in [Figure 3](#f3-ott-7-1733){ref-type="fig"}, ETV4 staining was mainly localized to the nuclei of cancer cells. ETV4 staining was not detected in any of the normal breast tissue. In contrast, strong ETV4 staining was observed in the tumor cells of TNBC. Using the median staining score of ETV4 in TNBC as a cutoff value, 77/135 (57.0%) cases displayed high levels of ETV4 expression and 58/135 (43.0%) cases displayed low levels of ETV4 expression in TNBC tissue.

Association of ETV4 expression with clinical outcome of TNBC patients
---------------------------------------------------------------------

We then associated ETV4 expression with clinicopathological parameters from these 135 patients. The association between ETV4 protein expression and various clinicopathological parameters is listed in [Table 2](#t2-ott-7-1733){ref-type="table"}. Specifically, compared with tumors with low ETV4 protein expression, patients with ETV4 highly expressed tumors have advanced AJCC stage and a higher proportion of positive lymph node and lymphovascular invasion ([Table 2](#t2-ott-7-1733){ref-type="table"}).

Next, we associated ETV4 expression with recurrence and survival of the patients. Up to December 2011, the median follow-up time was 74 months (range, 8--150 months). Among all 135 patients, 30 cases relapsed and 28 cases died. The 5-year DFS and OS of all patients were 74.5% and 85.1%, respectively. According to the sites of first relapse, ten patients had developed a locoregional recurrence and 26 patients had developed a distant metastasis. When the patients were stratified in terms of the expression level of ETV4 protein, the 5-year DFS in tumors with low ETV4 expression and high expression was 89.7% and 63.4%, respectively (*P*=0.001). The 5-year OS of patients with low ETV4 expression and high expression was 93.1% and 79.2%, respectively (*P*=0.017). Compared with low ETV4 protein-expressed tumor, patients with high expression of ETV4 protein had a significantly higher risk in developing a distant metastasis (97.4% vs 73.1%, Fisher's exact test, *P*\<0.0001), whereas the risk for locoregional recurrence was not significantly different between these two groups (96.5% vs 90.7%, *P*=0.287) ([Figure 4A--D](#f4-ott-7-1733){ref-type="fig"}).

Univariate and multivariate analyses were performed and we found that positive lymph nodes, higher clinical stage, present lymphovascular invasion, and expression level of ETV4 protein were significantly associated with reduced DFS and OS in univariate analysis ([Tables 3](#t3-ott-7-1733){ref-type="table"} and [4](#t4-ott-7-1733){ref-type="table"}). Furthermore, the multivariate analysis showed that only high expression of ETV4 protein remained an independent prognostic factor for shorter DFS (*P*=0.021) ([Table 3](#t3-ott-7-1733){ref-type="table"}).

Discussion
==========

In this study, we first detected a total of eleven differentially expressed genes in TNBC tissue by human tumor metastasis PCR array analysis, of which ETV4 was the most differentially expressed gene (*P*=0.0033, [Table 1](#t1-ott-7-1733){ref-type="table"}). In addition, some studies suggested that ETV4 could promote cancer development and metastasis,[@b12-ott-7-1733]--[@b14-ott-7-1733],[@b16-ott-7-1733],[@b17-ott-7-1733] so we selected an ETV4 gene for further study. Our findings verified ETV4 overexpression in breast cancer cell lines and tissue samples. ETV4 protein was over-expressed in 57.0% of TNBC cases. ETV4 overexpression was associated with an advanced stage and a higher proportion of positive lymph node and lymphovascular invasion. Patients with an ETV4-overexpressed tumor had a significantly higher risk of developing distant metastasis and poor OS and DFS. Multivariate analysis showed that overexpression of ETV4 protein was an independent predictor of poor DFS of TNBC patients. The current study demonstrated that overexpression of ETV4 protein had an increased risk for developing distant metastasis and poor survival in TNBC patients. Further study will investigate whether ETV4 protein is a novel target for control of TNBC distant metastasis.

TNBC is characterized by a high probability of a distant metastasis, especially to the lung and brain,[@b4-ott-7-1733]--[@b6-ott-7-1733] which is due to aberrant expression of tumor metastasis-related genes.[@b7-ott-7-1733]--[@b9-ott-7-1733] Thus, in this study, we profiled differentially expression of some of these genes and found that a total of eleven such genes were altered. We then chose ETV4 for further verification and analysis. Indeed, ETV4 belongs to the PEA3 group of the Ets family of transcription factors, expression of which was suggested to be associated with tumor metastases for several types of human cancers.[@b13-ott-7-1733],[@b23-ott-7-1733]--[@b27-ott-7-1733] In this study, we confirmed that ETV4 was one of the most significantly upregulated genes in TNBC tissue.

Furthermore, in the current study, we showed that expression of both ETV4 mRNA and protein was noticeably upregulated in ER-negative cell lines, regardless of HER2 status. Our current data were in agreement with those reported recently by Baert et al.[@b18-ott-7-1733] We also showed that expression of both ETV4 mRNA and protein in TNBC tissue was significantly higher than in the adjacent normal breast tissue. With further examination by IHC in our TMAs of TNBC, we found that 57.0% of TNBC tissue exhibited high expression of ETV4 protein. A similar frequency (53%) of ETV4 protein expression was observed by Qin et al.[@b28-ott-7-1733] Nevertheless, Bieche et al[@b19-ott-7-1733] reported that expression of ETV4 mRNA was detected in only 14% of unselected breast cancer tissue, and the level of ETV4 expression had a significant negative correlation with the level of ER, while Benz et al[@b29-ott-7-1733] reported that ETV4 mRNA expression was overexpressed in 76% of Her2-positive breast cancer tissue. It is unknown what contributed to this discrepancy. However, it is well known that both TNBC and Her2-positive breast cancer represent two aggressive breast cancer subtypes and they share several common characteristics such as a higher risk of distant metastasis and a poor prognosis.[@b4-ott-7-1733],[@b5-ott-7-1733],[@b30-ott-7-1733] These findings suggested that ETV4 might be especially highly expressed in breast cancer cells with an invasive phenotype.

In addition, in this study, we found that overexpression of ETV4 protein was positively associated with lymph node involvement, lymphovascular invasion, and advanced clinical stage. Patients with ETV4 overexpression had a significantly shorter DFS and OS. Importantly, our results also show that overexpression of ETV4 protein increased the risk of developing a distant metastasis in TNBC patients, rather than locoregional recurrence. These data further suggest that ETV4 overexpression could promote progression and metastasis of TNBC. Our further multivariate analysis showed that ETV4 overexpression was an independent predictor of short DFS of TNBC patients. This result is consistent with previous studies in other cancers.[@b25-ott-7-1733],[@b27-ott-7-1733],[@b31-ott-7-1733],[@b32-ott-7-1733]

Mechanistically, the PEA3 subfamily of ETS-domain transcription factors has been shown to be an important driver of cancer cell metastasis.[@b23-ott-7-1733] Overexpressed ETV4 enhances transcription of different target genes involved in tumor metastasis, such as MMP genes.[@b26-ott-7-1733],[@b27-ott-7-1733],[@b33-ott-7-1733] These latter genes are involved in degrading the extracellular matrix to permit cancer metastasis.[@b34-ott-7-1733]--[@b36-ott-7-1733]

Conclusion
==========

Our current study detected eleven differentially expressed tumor metastasis-related genes in TNBC tissue, and further investigation showed that ETV4 upregulated in more than half of the TNBC tissue specimens. ETV4 overexpression was not only a marker of tumor aggressiveness but also a poor prognostic marker for ER-negative patients, including TNBC. Further studies of ETV4 could help to define the molecular mechanism responsible for TNBC distant metastasis and offer potentially novel strategies for future control of TNBC distant metastasis.
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![Relative expression comparison for 84 metastasis-related genes between triple-negative breast cancer (TNBC) and luminal A breast cancer tissue detected using a Human Tumor Metastasis RT^2^ Profiler™ PCR Array.\
**Notes:** The figure depicts a log transformation plot of the relative expression level of each gene (ΔΔCt) between TNBC (y-axis) and luminal A (x-axis). The red lines indicate a three-fold change in gene expression threshold.\
**Abbreviations:** PCR, polymerase chain reaction; ETV4, ETS translocation variant 4; MMP, matrix metalloproteinase.](ott-7-1733Fig1){#f1-ott-7-1733}

![Verification of ETS translocation variant 4 (ETV4) overexpression in triple-negative breast cancer (TNBC) cell lines and tissue.\
**Notes:** (**A**) Western blot analysis of ETV4 protein expression in TNBC cell lines and hormone receptor-positive cell lines. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as a loading control. (**B**) Real-time reverse transcription analysis of ETV4 messenger ribonucleic acid (mRNA) expression in TNBC cell lines and hormone receptor-positive cell lines. Transcript levels were normalized to GAPDH. (**C**) Western blot analysis of ETV4 protein expression in TNBC tissue (T) and adjacent normal breast tissue (ANT); GAPDH was used as a loading control. (**D**) Real-time reverse transcription analysis of ETV4 mRNA expression in TNBC tissue and adjacent normal breast tissue; expression data were normalized to GAPDH. Error bars represent the mean ± standard deviation from three independent experiments; \**P*\<0.05. (**E**) Immunohistochemistry staining of corresponding TNBC tissue (T) and adjacent normal breast tissue (ANT).\
**Abbreviation:** ER, estrogen receptor.](ott-7-1733Fig2){#f2-ott-7-1733}

![Representative ETS translocation variant 4 immunohistochemistry staining of normal breast tissue and archived triple-negative breast cancer tissue.](ott-7-1733Fig3){#f3-ott-7-1733}

![Association of ETS translocation variant 4 expression with poor prognosis of triple-negative breast cancer patients.\
**Notes:** (**A**) Disease-free survival; (**B**) overall survival; (**C**) locoregional relapse-free survival; (**D**) distant metastasis-free survival.](ott-7-1733Fig4){#f4-ott-7-1733}

###### 

Changes in relative expression for tumor metastasis genes between triple-negative breast cancer (TNBC) and luminal A breast cancer tissue

  Gene      Fold change TNBC/luminal A   *t*-test *P*-value   Average raw Ct TNBC   Average raw Ct luminal A
  --------- ---------------------------- -------------------- --------------------- --------------------------
  *CCL7*    3.06                         0.0196               26.76                 28.21
  *ETV4*    5.76                         0.0033               24.78                 28.39
  *KISS1*   3.02                         0.0329               27.98                 29.40
  *MET*     4.39                         0.0184               23.51                 25.48
  *MMP7*    6.09                         0.0264               20.07                 22.51
  *NR4A3*   3.20                         0.0119               25.33                 26.84
  *TIMP3*   4.39                         0.0309               31.38                 33.34
  *TSHR*    4.48                         0.0190               25.95                 27.94
  *ITGA7*   −8.25                        0.0063               35.00                 31.79
  *MMP2*    −3.02                        0.0101               20.13                 18.37
  *SSTR2*   −4.88                        0.0234               27.00                 24.55

**Notes:** The table lists genes that exhibit at least a three-fold difference in expression in the TNBC tissue when compared with the luminal A breast cancer tissue. The raw threshold cycle (Ct) values seen in the two samples are also listed for comparison.

**Abbreviations:** ETV4, ETS translocation variant 4; MMP, matrix metalloproteinase.

###### 

Association ETV4 protein expression and clinicopathological parameters from TNBC patients

  Variable                         Total population   ETV4          *P*-value     
  -------------------------------- ------------------ ------------- ------------- -----------------------
  Total                            135                58 (43.0)     77 (57.0)     
  Median age (range), years        49 (16--76)        49 (27--76)   49 (16--72)   0.641 (Mann--Whitney)
  Age, n (%)                                                                      
   ≤35 years                       31 (23.0)          15 (48.4)     16 (51.6)     0.311
   \>35 years                      104 (77.0)         43 (41.3)     61 (58.7)     
  Menopausal status, n (%)                                                        
   Premenopausal                   78 (57.8)          34 (43.6)     44 (56.4)     0.502
   Postmenopausal                  57 (42.2)          24 (42.1)     33 (57.9)     
  Tumor size, n (%)                                                               
   ≤2 cm                           33 (24.4)          18 (54.5)     15 (45.5)     0.090
   \>2 cm                          102 (75.6)         40 (39.2)     62 (60.8)     
  Lymph node status, n (%)                                                        
   Negative                        63 (46.7)          37 (58.7)     26 (41.3)     \<0.0001
   Positive                        72 (53.3)          21 (29.2)     51 (70.8)     
  AJCC stage, n (%)                                                               
   I/II                            93 (68.9)          52 (55.9)     41 (44.1)     \<0.0001
   III                             42 (31.1)          6 (14.3)      36 (85.7)     
  Histological grade, n (%)                                                       
   I/II                            39 (28.9)          20 (51.3)     19 (48.7)     0.146
   III                             96 (71.1)          38 (39.6)     58 (60.4)     
  Lymphovascular invasion, n (%)                                                  
   Yes                             36 (26.7)          8 (22.2)      28 (77.8)     0.003
   No                              99 (73.3)          50 (50.5)     49 (49.5)     

**Note:** The chi-square test was used.

**Abbreviations:** ETV4, ETS translocation variant 4; TNBC, triple-negative breast cancer; AJCC, American Joint Committee on Cancer.

###### 

Univariate and multivariate analysis of disease-free survival in 135 patients with triple-negative breast cancer

  Variables                             N        Univariate   Multivariate                               
  ------------------------------------- -------- ------------ -------------- ------- ------ ------------ -------
  Age, years (≤35 vs \>5)               31/104   2.15         0.91--5.11     0.083   1.86   0.76--4.51   0.172
  Tumor size, cm (≤2 vs \>2)            33/102   0.89         0.45--1.77     0.739   0.75   0.36--1.58   0.452
  Node status (negative vs positive)    63/72    2.89         1.45--5.73     0.002   1.84   0.80--4.30   0.160
  Stage (I/II vs III)                   93/42    2.18         1.20--3.98     0.011   0.98   0.34--2.86   0.977
  Histological grade (I/II vs III)      39/96    1.17         0.59--2.31     0.662   0.94   0.46--1.94   0.875
  Lymphovascular invasion (no vs yes)   99/36    2.10         1.14--3.88     0.018   1.33   0.45--3.94   0.602
  ETV4 expression (lower vs high)       58/77    3.27         1.57--6.83     0.002   2.58   1.15--5.77   0.021

**Note:**

HR and 95% CIs were calculated using Cox regression analysis.

**Abbreviations:** HR, hazard ratio; CI, confidence interval; ETV4, ETS translocation variant 4.

###### 

Univariate and multivariate analysis of overall survival in 135 patients with triple-negative breast cancer

  Variables                             N        Univariate   Multivariate                               
  ------------------------------------- -------- ------------ -------------- ------- ------ ------------ -------
  Age, years (≤35 vs \>35)              31/104   2.96         0.89--9.82     0.077   2.81   0.82--9.61   0.099
  Tumor size, cm (≤2 vs \>2)            33/102   0.85         0.36--2.02     0.711   0.64   0.25--1.63   0.349
  Node status (negative vs positive)    63/72    2.77         1.18--6.51     0.020   1.45   0.49--4.30   0.505
  Stage (I/II vs III)                   93/42    2.34         1.11--4.91     0.025   0.81   0.18--3.62   0.786
  Histological grade (I/II vs III)      39/96    1.06         0.46--2.41     0.895   1.04   0.44--2.46   0.925
  Lymphovascular invasion (no vs yes)   99/36    2.56         1.22--5.39     0.013   2.26   0.51--9.93   0.280
  ETV4 expression (lower vs high)       58/77    2.85         1.16--7.04     0.023   2.09   0.76--5.76   0.153

**Note:**

HR and 95% CIs were calculated using Cox regression analysis.

**Abbreviations:** HR, hazard ratio; CI, confidence interval; ETV4, ETS translocation variant 4.
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